Companies › Phanes Therapeutics
3 active drug programs in 3 registered trials: 3 Phase 1; Oncology; next expected readout Dec 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Mavrostobart (PT199) anti-CD73 monoclonal antibody | NT5E | Phase 1 | Non Small Cell Lung Cancer | Dec 2027 |
| Peluntamig (PT217) Bispecific antibody against DLL3 and CD47 | DLL3, CD47 | Phase 1 | Small Cell Lung Cancer (SCLC) | Dec 2027 |
| Spevatamig (PT886) Bispecific antibody targeting Claudin 18.2 and CD47 | CLDN18, CD47 | Phase 1 | Gastric or Gastroesophageal Junction Adenocarcinoma | Dec 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05431270 | Mavrostobart (PT199) | Phase 1 | Non Small Cell Lung Cancer | Oncology | Dec 2027 |
| NCT05652686 | Peluntamig (PT217) | Phase 1 | Small Cell Lung Cancer (SCLC) | Oncology | Dec 2027 |
| NCT05482893 | Spevatamig (PT886) | Phase 1 | Gastric or Gastroesophageal Junction Adenocarcinoma | Oncology | Dec 2027 |
AstraZeneca Akeso Novartis Astellas Boehringer Ingelheim Beijing Biotech ALX Oncology Pfizer Suzhou Suncadia Biopharmaceuticals Ono Pharmaceutical
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.